Neurotech International Limited (ASX:NTI) has issued ordinary fully paid shares in the capital of the company, as disclosed in a secondary trading notice lodged pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth), dated 17 November 2026.
Key Points
- Neurotech International issued ordinary fully paid shares as detailed in the Appendix 2A released on 17 November 2026.
- The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth).
- The company confirmed compliance with Chapter 2M of the Corporations Act and sections 674 and 674A as at the date of the notice.
- The company stated there is no excluded information, as defined under section 708A(7) of the Corporations Act, that investors and their professional advisers would reasonably expect to find in a disclosure document.
Share Issuance and Secondary Trading Notice Details
Neurotech International Limited issued ordinary fully paid shares in the capital of the company, with the issuance referenced in the Appendix 2A lodged on 17 November 2026. The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth). The company lodged the secondary trading notice pursuant to section 708A(5)(e) of the Corporations Act to facilitate the secondary trading of those shares on the ASX. The filing was authorised for release by the Board of Neurotech International Limited.
Regulatory Compliance Confirmation
As at the date of the notice, Neurotech International confirmed it has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the company, as well as sections 674 and 674A of the Corporations Act. The company also stated that, as at the date of the notice, there is no information to be disclosed that constitutes excluded information as defined in section 708A(7) of the Corporations Act that investors and their professional advisers would reasonably expect to find in a disclosure document.
Company Background: Clinical-Stage Biopharmaceutical Focus
Neurotech International Limited is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders, with a broad-spectrum oral cannabinoid drug therapy called NTI164. According to the filing, the company has commenced dosing on a pivotal Phase III trial in Autism Spectrum Disorder and has completed Phase I/II trials in ASD, PANDAS/PANS, and Rett Syndrome. Neurotech has also received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.



Please wait processing your request...